EP
LOGC

Eversept Partners’s LogicBio Therapeutics, Inc. Common Stock LOGC Stock Holding History

Eversept Partners’s Portfolio LOGC Stock Details LOGC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q1 		– Sell
-291,101
Closed -$672K – 114
2021
Q4 		$672K Sell
291,101
-58,818
-17% -$199K 0.04% 95
2021
Q3 		$1.6M Buy
+349,919
New +$1.54M 0.11% 84

Other funds holding LOGC

O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
HCA
Harbor Capital Advisors Chicago, Illinois $1.23B AUM 30.56% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
SCM
Sio Capital Management New York $697M AUM 79.73% 1-Year Est. Return

Eversept Partners's LOGC Position: Q1 2022 in Review

Eversept Partners sold out of LogicBio Therapeutics, Inc. Common Stock (LOGC) in Q1 2022, closing a stake of 291,101 shares — an estimated $672K sold.

Eversept Partners first reported a position in LOGC in Q3 2021 and held it in 2 quarters. The position peaked at $1.6M in Q3 2021. 46 funds tracked by Wall St. Rank hold LOGC as of Q1 2022.

  • Eversept Partners reported no remaining LogicBio Therapeutics, Inc. Common Stock position as of Q1 2022 after selling out during the quarter.
  • Eversept Partners sold 291,101 LogicBio Therapeutics, Inc. Common Stock shares in Q1 2022, an estimated $672K.
  • Eversept Partners first reported a position in LogicBio Therapeutics, Inc. Common Stock in Q3 2021 and held it in 2 quarters.
  • Eversept Partners's LogicBio Therapeutics, Inc. Common Stock position peaked at $1.6M in Q3 2021.
  • 46 funds tracked by Wall St. Rank held LogicBio Therapeutics, Inc. Common Stock as of Q1 2022.

Based on Eversept Partners's 13F filing for Q1 2022, filed 16 May 2022.